13F filing recap · Q1 2017

What did Chou Associates buy in Q1 2017?

Reported stock-position changes between this filing and the previous one.

Stock value

$296.52M

Positions

Estimated turnover

18.9%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

ENDPEndo International Plc$10.60Mreported value+950.0K shares TEVATeva Pharmaceutical Industries Limited$6.90Mreported value+215.0K shares

Increased positions

VRXValeant Pharmaceuticals International, Inc.$25.96Mreported value+393.0K shares+20.0%SDSandridge Energy, Inc.$2.90Mreported value+108.4K shares+224.7%

Reduced positions

JPMJPMorgan Chase & Co$29.01Mreported value-500.0K shares-44.4%NOKNokia Corp$14.90Mreported value-1.00M shares-26.7%BAC WS ABank of America Corp$6.07Mreported value-300.0K shares-35.8%

Exited positions

AZNAstrazeneca Plc$711.0Kprior reported value-13.0K shares-100.0%GSKGsk Plc$347.0Kprior reported value-18.0K shares-100.0%